Cibus US et Drug Administration (infra post FDA appellatum) approbavit Portrazza (necitumumab) in compositione cum gemcitabine et cisplatina in tractatione squamosa non parva cell cancri pulmonis in 24 Novembris 2015, primo Approbata. curatio prima-linea aegrorum cum provectioribus squamosis non-parvis pulmonis cellae cancri.
Lung cancer is currently the malignant tumor with the highest morbidity and mortality, with more than 1 million deaths due to lung cancer worldwide each year. According to clinical and histopathological characteristics, lung cancer can be roughly divided into two types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), of which non-small cell lung cancer accounts for about 85% of all lung cancers. Non parva cellula pulmonis cancer can be further divided into squamous and non-squamous non-small cell lung cancer, which includes lung adenocarcinoma. Squamous non-small cell pulmonis cancer, accounts for about 30% of all lung cancers. The prognosis of patients is poor, and the 5-year survival rate is less than 5%. The research and treatment of squamous NSCLC lags far behind lung ADENOCARCINOMA. One of the important reasons is that there are too few driving gene markers known to help make clinical treatment decisions. The targeted treatment of lung squamous cell carcinoma faces difficulties and challenges . Because of the greater risk of pulmonary hemorrhage, bevacizumab is not recommended for lung squamous cell carcinoma. Due to economic utility considerations, cetuximab is also limited. As of now, its first-line treatment still has huge medical needs.
At present, the first-line treatment plan for the treatment of squamous non-small cell lung cancer at home and abroad is platinum-containing two-drug chemotherapy (studies have confirmed that cisplatin combined with gemcitabine is more effective), and the second-line treatment abroad is docetaxel or docetaxel combined with a new target Xiang, immunotherapy drugs nivolumab and ramucirumab. Among them, nivolumab is the immunotherapy drug OPDIVO (PD-1 inhibitor), and ramucirumab is an anti-vascular endothelial growth factor (VEGF) inhibitor. These targeted drugs are not listed in the country. This time, Portrazza was approved for use in combination with gemcitabine and cisplatin, becoming the first targeted drug approved for first-line treatment of patients with advanced squamous non-small cell lung cancer.
Necitumumab (trade name: Portrazza) is a human recombinant IgG1 monoclonal antibody of EGFR. EGFR (epidermal growth factor receptor) is a multifunctional glycoprotein widely distributed on the cell membrane of various tissues of the human body. It is a tyrosine kinase Type receptor is one of the four members of the HER / ErbB family, and its mutation or overexpression is associated with malignant phenotypes such as malignant proliferation, inhibition of apoptosis, local infiltration, vascularization, and tuberculum metastasis of tumor cells.
Necitumuma salus et efficacia studium visum est in prima linea multi-centri, randomized, periodum apertam III QUADRIVIUM clinicum, quod comprehendit 1,093 aegros cum squamosa non parva cellula pulmonis cancri progresso. Aegri passim in duos circulos divisi sunt et Gemcitabinum + cisplatinum + Necitumumab (GP regimen cum Necitumumab) compositum, et gemcitabinum + cisplatina sola therapia (GP sola regimen).
Eventus suggerunt GP cum necitumumumab curatione coniunctum coetum significanter meliorem altiore superesse (HR 0.84; 95% CI: 0.74-0.96; p = 0.01) cum GP chemotherapy solum globo comparatum, et medianum tempus aegrorum superstitem esse 11.5 menses (95. % CI: 10.4-12.6) et superstes tempus globi gemcitabini + cisplatini duorum medicamentorum 9.9 mensium (95% CI: 8.9-11.1), et periculum mortis redactum est per 16% in trium medicamentorum compositione. Circulus et medius duorum circulorum non processit Superstites periodi erant 5.7 vs 5.5 menses. Sed necitumumab aegrotis curatione non parvae pulmonis cancri non-squamoso est efficax.
Frequentiores effectus latus Necitumumab includunt temeraria et hypomagnesemia, quae vicissim debilitatem musculus, epilepsiam, pulsationem irregularem, etc. Subita cardiaca comprehensio et mors repentina etiam fieri potest, ut medicus praescribens sedulo indiget.
Dr. Richard Pazdur, caput Department of Hematologiae et Oncologiae productorum apud FDA Centrum pro medicamentis Aestimationis et Investigationis dixit: " Genera cancri pulmonis multum variant, ideo electio curationis pendet a specie patientis. Portrazza hodie probata est pulmonis squamosa carcinoma cellae Nova optio aegris ut prorogetur ad salutem. "
Necitumumab (nomen artis: Portrazza) ab Eli Lilium venale est et societas Americae Foederatae. Nivolumab (nomen artis OPDIVO approbatum ad tractationem cancri squamosi non parvae cellae pulmonis die 22 Iunii 2015) in articulo memorato pertinet ad Bristol-Myers Squibb, ramucirumab (nomen trade: Cyramza, probatum ad tractationem squamosi. non-cancri pulmonis cellulae parvae die 21 Aprilis 2014) Productum etiam est Eli Lilium Civitatum Americae Unitarum. Haec tria medicamenta ruri non numerantur.
